5
Dec

Research shows patients ineligible for studies may benefit from trial participation

Some leukemia patients with existing medical conditions may be safely treated

Patients who potentially could benefit most from participation in clinical trials due to poor prognoses often are not included based on eligibility criteria, drugs such as existing medical illnesses. A novel study at The University of Texas MD Anderson Cancer Center revealed some patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), rx who traditionally could not be considered for clinical trials, unhealthy responded well and were safely treated in this setting.

The study, led by Guillermo Garcia-Manero, M.D., professor of Leukemia, followed 109 patients with AML and MDS undergoing treatment with azacitidine (AZA) and vorinostat. Research results were presented Dec. 3 at the 58th Annual Meeting of the American Society for Hematology in San Diego.

Read Full Article Here >>